...Welcome, everybody, to Recursion's L(earnings) call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025, and the time ahead. So with that, we'll jump into the slides, and I want to just set the stage, first of all, to share a little bit about the moment in time that we're in right now. Recursion is leading this field of TechBio. We're the frontier of this exciting opportunity to decode biology to change the way that drugs are discovered and developed. And I think what we're seeing in 2024 at Recursion are leading indicators of what this inevitable future may look like. And what we're going to see moving into 2025 now is a cascade of proof points that are going to make it more and more obvious to everyone about what the future of the biopharma industry looks like. Now to talk a little bit about how we've gotten to this place in 2024, I want to dive into some of the year-end review, so to speak. And I want to kick that off by talking about our...
